循环肿瘤DNA在原发性纵隔大B细胞淋巴瘤中的中期评估:LYSA多中心研究
该前瞻性多中心观察研究纳入84例初诊PMBL患者,在基线及2、4周期后采集血浆与PET,用高深度纠错测序检测ctDNA-MRD。4周期后MRD持续存在者PFS显著缩短,MRD4对疾病进展的阳性预测值高于PET4,且仅PET4-/MRD4-与PFS独立相关,提示ctDNA监测可补充PET反应评估。
要点
- 4周期后MRD持续存在与PFS显著缩短相关(HR 78.1)。
- MRD4对疾病进展的阳性预测值89%,高于PET4的50%。
- 仅PET4-/MRD4-在多变量分析中与PFS独立相关。
核心结论
- 前线治疗后ctDNA-MRD检测强烈补充PET反应标准以预测结局。
- 支持将ctDNA监测作为PMBL未来风险适配策略的有价值工具。
研究设计与样本
- 前瞻性多中心观察研究,纳入84例初诊PMBL患者。
- 基线及2、4周期后采集血浆与PET图像。
- ctDNA与肿瘤活检采用高深度纠错测序分析,检测限约10^-3。
- 评估MRD、PET反应与无进展生存(PFS)之间的关联。
主要发现
- 84例患者中基线ctDNA检出率为98%。
- 4周期R-CHOP14或R-ACVBP治疗后87.7%患者MRD不可测。
- 4周期后MRD持续存在(MRD4)与更短PFS相关(HR 78.1;95%CI 9.5-641.8)。
- MRD4不可测者1年PFS为98.4%(95%CI 95.4%-100%),可测者为33.3%(95%CI 13.2%-84.0%),P<10^-4。
- MRD4对疾病进展的阳性预测值89%高于PET4的50%,阴性预测值相似(100% vs 93%)。
关键数值与推荐
- 多变量分析中仅PET4-/MRD4-与PFS保持关联(校正HR 0.07;95%CI 0.01-0.90)。
临床怎么用
- 可在基线及治疗中采集血浆行ctDNA-MRD检测以辅助PMBL风险分层。
- 4周期后MRD持续存在提示进展风险高,需结合PET综合判断。
- MRD4阴性者进展风险极低,可能支持风险适配策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary mediastinal large B-cell lymphoma (PMBL) achieves excellent outcomes with dose-dense immunochemotherapy, yet response assessment by positron emission tomography (PET) remains limited. In this prospective multicenter observational study, we evaluated the clinical relevance of circulating tumor DNA (ctDNA) minimal residual disease (MRD) in patients with newly diagnosed PMBL and assessed whether MRD enhances outcome discrimination beyond PET. Plasma and PET images were collected at baseline and after 2 and 4 cycles. ctDNA and tumor biopsy were analyzed by high-depth, error-corrected sequencing (limit of detection ∼10-3). Associations between MRD, PET response, and progression-free survival (PFS) were evaluated. Among 84 patients, baseline ctDNA was detected in 98%. After 4 cycles of treatment with R-CHOP14 (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, administered every 14 days) or R-ACVBP (rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone), 87.7% had undetectable MRD. Persistence of minimal residual disease after 4 cycles of therapy (MRD4) was associated with shorter PFS (hazard ratio [HR], 78.1; 95% confidence interval [CI], 9.5-641.8). The 1-year PFS was 98.4% (95% CI, 95.4%-100%) for patients with undetectable MRD4 vs 33.3% (95% CI, 13.2%-84.0%) for patients with detectable MRD4 (P < 10^-4). MRD4 showed a higher positive predictive value (89% vs 50%) for disease progression than PET4, (PET after 4 cycles of chemotherapy) maintaining a similar negative predictive value (100% vs 93%). In multivariate analysis, only PET4-/MRD4- remained associated with PFS (adjusted HR, 0.07; 95% CI, 0.01-0.90). Plasma ctDNA represents a highly abundant source of genetic markers for tumor fingerprinting and disease monitoring. MRD detection after frontline therapy strongly complements PET response criteria in predicting outcome. These findings support the use of ctDNA monitoring as a valuable tool for future risk-adapted strategies in PMBL. This trial was registered at www.clinicaltrials.gov as NCT04980222.
引用
- Camus V, Krzisch D, Bruscaggin A, et al. Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study. Blood Adv. 2026. PMID: 41979332. doi:10.1182/bloodadvances.2025019108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。